{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:58:42Z","timestamp":1789167522136,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":61,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16270-1","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:23:51Z","timestamp":1780039431000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["[\u00b9\u2077\u2077Lu]Lu-FAPI-2286 radioligand therapy in heavily pre-treated patients with advanced breast and gastrointestinal cancers: a single-center retrospective experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Faeze","family":"Rabani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Hadi","family":"Samadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Sadeghpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Barashki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Emadi Torghabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ehsan","family":"Soltani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atena","family":"Aghaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"issue":"1","key":"16270_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"16270_CR2","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1016\/j.annonc.2020.09.010","volume":"31","author":"F Cardoso","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, Andr\u00e9 F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31(12):1623\u201349.","journal-title":"Ann Oncol"},{"issue":"2","key":"16270_CR3","doi-asserted-by":"publisher","first-page":"167","DOI":"10.6004\/jnccn.2022.0008","volume":"20","author":"JA Ajani","year":"2022","unstructured":"Ajani JA, D\u2019Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, et al. Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20(2):167\u201392.","journal-title":"J Natl Compr Canc Netw"},{"key":"16270_CR4","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A, Abdlkadir AS, Ruzzeh S, Abdulrahman M, Moghrabi S, Ahmed R et al. [(177)Lu]Lu-FAPI Radioligand Therapy: Emerging Horizons and Clinical Promise in Solid Tumors: A Comprehensive Review. Semin Nucl Med. 2025;55(6);988\u201398.","DOI":"10.1053\/j.semnuclmed.2025.06.010"},{"issue":"7","key":"16270_CR5","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","volume":"50","author":"BM Priv\u00e9","year":"2023","unstructured":"Priv\u00e9 BM, Boussihmad MA, Timmermans B, van Gemert WA, Peters SMB, Derks YHW, et al. Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies. Eur J Nucl Med Mol Imaging. 2023;50(7):1906\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"16270_CR6","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"20","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM, et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer. 2020;20(3):174\u201386.","journal-title":"Nat Rev Cancer"},{"key":"16270_CR7","doi-asserted-by":"publisher","unstructured":"Sadeghpour S, Aghaee A, Sadeghpour S, Rizzo A, Pizzuto DA, Annunziata S et al. Predicting the unpredictable: prognostic and predictive power of FAPI-PET imaging in oncology: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2026;53:2927\u201338. https:\/\/doi.org\/10.1007\/s00259-025-07735-9. Epub 2026 Jan 27. PMID: 41588207.","DOI":"10.1007\/s00259-025-07735-9"},{"issue":"3","key":"16270_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s00259-025-07576-6","volume":"53","author":"S Sadeghpour","year":"2026","unstructured":"Sadeghpour S, Aghaee A, Ahmadzadehfar H, Rizzo A, Treglia G, Sadeghi R. Revealing the hidden: A systematic review and meta-analysis of FAPI-based tracers imaging for brain metastatic lesions. Eur J Nucl Med Mol Imaging. 2026;53(3):1419\u201333.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"16270_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.2967\/jnumed.124.269002","volume":"66","author":"TA Hope","year":"2025","unstructured":"Hope TA, Calais J, Goenka AH, Haberkorn U, Konijnenberg M, McConathy J, et al. SNMMI Procedure Standard\/EANM Practice Guideline for Fibroblast Activation Protein (FAP) PET. J Nucl Med. 2025;66(1):26\u201333.","journal-title":"J Nucl Med"},{"issue":"11","key":"16270_CR10","doi-asserted-by":"publisher","first-page":"6857","DOI":"10.1016\/j.acra.2025.05.053","volume":"32","author":"Y Zhao","year":"2025","unstructured":"Zhao Y, Wang S, Du B, Cui Y, Wang Y, Wang Y, et al. Head-to-head Comparison of [(68)Ga]Ga-FAPI-04 PET and [(18)F]FDG PET in the Evaluation of Primary Gastrointestinal Tumors and Metastases: A Systematic Review and Meta-analysis. Acad Radiol. 2025;32(11):6857\u201372.","journal-title":"Acad Radiol"},{"issue":"9","key":"16270_CR11","doi-asserted-by":"publisher","first-page":"4084","DOI":"10.7150\/thno.106108","volume":"15","author":"S Ruzzeh","year":"2025","unstructured":"Ruzzeh S, Abdlkadir AS, Paez D, Kang KW, Watabe T, Moghrabi S, et al. Therapeutic potential of FAPI RLT in oncology: A systematic review. Theranostics. 2025;15(9):4084\u2013100.","journal-title":"Theranostics"},{"issue":"11","key":"16270_CR12","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","volume":"49","author":"D Zboralski","year":"2022","unstructured":"Zboralski D, Hoehne A, Bredenbeck A, Schumann A, Nguyen M, Schneider E, et al. Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy. Eur J Nucl Med Mol Imaging. 2022;49(11):3651\u201367.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"16270_CR13","doi-asserted-by":"publisher","unstructured":"Fouillet J, Torchio J, Rubira L, Fersing C. Unveiling the Tumor Microenvironment Through Fibroblast Activation Protein Targeting in Diagnostic Nuclear Medicine: A Didactic Review on Biological Rationales and Key Imaging Agents. Biology (Basel). 2024;13(12):967. https:\/\/doi.org\/10.3390\/biology13120967.","DOI":"10.3390\/biology13120967"},{"key":"16270_CR14","doi-asserted-by":"publisher","first-page":"1628158","DOI":"10.3389\/fmed.2025.1628158","volume":"12","author":"M Ammour","year":"2025","unstructured":"Ammour M, Torchio J, Renaud SC, Rubira L, Fersing C. Specific reaction conditions for efficient automated (68)Ga-radiolabeling of the FAP-2286 pseudopeptide on a GAIA(\u00ae) synthesizer. Front Med (Lausanne). 2025;12:1628158.","journal-title":"Front Med (Lausanne)"},{"issue":"9","key":"16270_CR15","doi-asserted-by":"publisher","first-page":"e564","DOI":"10.1097\/RLU.0000000000005753","volume":"50","author":"N Raeisi","year":"2025","unstructured":"Raeisi N, Saber Tanha A, Jafari Zarrin Ghabaei F, Barashki S, Aryana K. Favorable Palliative Effect of 177 Lu-FAPI-2286 in Two Breast Cancer Patients With Refractory Bone Pains. Clin Nucl Med. 2025;50(9):e564\u20137.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"16270_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s44303-024-00053-z","volume":"2","author":"Y Mori","year":"2024","unstructured":"Mori Y, Novruzov E, Schmitt D, Cardinale J, Watabe T, Choyke PL, et al. Clinical applications of fibroblast activation protein inhibitor positron emission tomography (FAPI-PET). npj Imaging. 2024;2(1):48.","journal-title":"npj Imaging"},{"issue":"7","key":"16270_CR17","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/nm.3886","volume":"21","author":"LR Yates","year":"2015","unstructured":"Yates LR, Gerstung M, Knappskog S, Desmedt C, Gundem G, Van Loo P, et al. Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med. 2015;21(7):751\u20139.","journal-title":"Nat Med"},{"issue":"6472","key":"16270_CR18","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1126\/science.aav4474","volume":"366","author":"M Russo","year":"2019","unstructured":"Russo M, Crisafulli G, Sogari A, Reilly NM, Arena S, Lamba S, et al. Adaptive mutability of colorectal cancers in response to targeted therapies. Science. 2019;366(6472):1473\u201380.","journal-title":"Science"},{"issue":"1","key":"16270_CR19","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","volume":"52","author":"SS Banihashemian","year":"2024","unstructured":"Banihashemian SS, Akbari ME, Pirayesh E, Divband G, Abolhosseini Shahrnoy A, Nami R, et al. Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma. Eur J Nucl Med Mol Imaging. 2024;52(1):237\u201346.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"20","key":"16270_CR20","doi-asserted-by":"publisher","first-page":"s6243","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman RE. Clinical Features of Metastatic Bone Disease and Risk of Skeletal Morbidity. Clin Cancer Res. 2006;12(20):s6243\u20139.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"16270_CR21","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.118.215913","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Kratochwil C, Lindner T, Marschalek MM, Loktev A, Lehnert W, et al. <sup\u2009>\u200968\u2009Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers<\/sup\u2009>. J Nucl Med. 2019;60(3):386\u201392.","journal-title":"J Nucl Med"},{"key":"16270_CR22","doi-asserted-by":"publisher","unstructured":"Ballal S, Yadav MP, Moon ES, Kramer VS, Roesch F, Kumari S et al. First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2). Pharmaceuticals (Basel). 2021;14(12):1212. https:\/\/doi.org\/10.3390\/ph14121212. PMID: 34959613; PMCID: PMC8707268.","DOI":"10.3390\/ph14121212"},{"issue":"11","key":"16270_CR23","doi-asserted-by":"publisher","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","volume":"46","author":"M Assadi","year":"2021","unstructured":"Assadi M, Rekabpour SJ, Jafari E, Divband G, Nikkholgh B, Amini H, et al. Feasibility and Therapeutic Potential of 177Lu-Fibroblast Activation Protein Inhibitor-46 for Patients With Relapsed or Refractory Cancers: A Preliminary Study. Clin Nucl Med. 2021;46(11):e523\u201330.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"16270_CR24","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1055\/s-0046-1820110","volume":"25","author":"DA Sweedat","year":"2026","unstructured":"Sweedat DA, Ruzzeh S, Abdlkadir AS, Moghrabi S, Abdulrahman M, Al-Ibraheem A. Fibroblast Activation Protein-Targeted Radioligand Therapy (FAP RLT) in Gastroenteropancreatic Malignancies: Biological Rationale, Clinical Evidence, and Future Directions. World J Nucl Med. 2026;25(1):3\u201311.","journal-title":"World J Nucl Med"},{"issue":"13","key":"16270_CR25","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1007\/s00259-024-06864-x","volume":"51","author":"S Kuyumcu","year":"2024","unstructured":"Kuyumcu S, Has-\u015eim\u015fek D. Evaluating the efficacy of [(177)Lu]Lu-FAP-2286 in combination therapy for metastatic breast cancer. Eur J Nucl Med Mol Imaging. 2024;51(13):4188\u20139.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16270-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16270-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16270-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:10:24Z","timestamp":1785517824000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16270-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16270"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16270-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the local committee (Mashhad University of Medical Sciences Ethical Committee) in accordance with the ethical code IR.MUMS.MEDICAL.REC.1404.119. The protocol was conducted in accordance with the ethical principles of the Declaration of Helsinki. All patients provided written informed consent to receive the unapproved radiopharmaceutical, acknowledging the experimental nature of the therapy, potential risks, and the collection of their clinical data for research purposes.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"905"}}